Lasofoxifene

 

Lasofoxifene

Lasofoxifene is being investigated as a potent, bioavailable selective estrogen receptor modulator (SERM) (also known as an estrogen agonist/antagonist) with a differentiated safety profile that could prove useful in the treatment of postmenopausal women and premenopausal women on ovarian suppression with locally advanced or metastatic estrogen receptor-positive (ER+) breast cancer. Lasofoxifene has been part of several clinical development programs and is being investigated as part of the ELAINE Study not only for its impacts on breast cancer but also its impacts on quality of life.

Hypothetical Mechanism of Action (MOA) of Lasofoxifene

Clinical scientists at the University of Chicago are using crystallography to better understand the MOA of lasofoxifene.